Heat Biologics completes patient enrollment for randomized arms of its phase 2 trial
Heat Biologics announced it has completed enrollment of the full 75 patients in the blinded, randomized, placebo-controlled arms of the Phase 2 clinical trial of HS-410 (vesigenurtacel-L) for treatment of high-risk, non-muscle invasive bladder cancer. October 08, 2015